Carac® is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.

IMPORTANT SAFETY INFORMATION

Carac® is contraindicated in women who are or may become pregnant, in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency, and in patients with known hypersensitivity to any of its components. In clinical trials, the most common drug-related adverse event was application site reaction (94.6%), which included: erythema, dryness, burning, erosion, pain, and edema. Some patients also experienced eye irritation (5.4%), including stinging and burning.

For more information, please see Full Prescribing Information for Carac®